Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Utilisation of the mesenchymal stem cell receptome for rational development of uniform, serum-free culture conditions and tools for cell characterization (PURSTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Ireland,Italy,United Kingdom,Czechia,Ireland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2012-04-30
Duration (months): 42.0
Total project cost (EUR): 3611567.8
EU funding (EUR): 2750367.0
Participants: 7
Project status: CLOSED

Stem cells offer a promising avenue to therapy for a wide range of complaints. However, for this potential to be realized, a consistent and plentiful supply of well-characterised stem cells is essential. There has been relatively little progress in the development of new culture technologies for the large-scale manufacture of mesenchymal stem cells (MSCs). There is a strong possibility that this limited ability to produce stem cells will result in delays to the translation of new therapies to the clinic. This will have a direct negative effect on the health of European citizens suffering from diseases untreatable by conventional medical technology and delay European efforts to promote “NanoMedicine - Nanotechnology for Health”. PurStem will progress the state of the art in the production of mesenchymal stem cells (MSCs) in large quantities. The current state of the art has several weaknesses - there are no standards for characterisation, isolation or identification of MSCs from any tissue, nor are there standard protocols for differentiation of MSCs to various lineages. Additionally, surface markers used for MSC characterization lack specificity and cryopreservation protocols are not standardized. Critically, current production methods for MSC require the use of animal products with major contaminant implications. PurStem will • Identify the MSC “receptome” and • Use this repertoire of growth factor receptors to • Develop novel serum-free media for MSC production. PurStem will also result in novel antibody reagents for specific MSC characterization and contribute to GMP manufacturing standards to enable rapid progression to production of serum-free MSC for clinical applications. The impact on a range of therapeutic and research domains of having a reliable supply of industrial levels of categorised MSCs will be significant. PurStem represents a key enabler for stem cell applications in a range of therapeutic fields.

Keywords: consistent industrial production of high-quality,well characterised mesenchymal stem cells for a range of therapies.
EuroDRG – Diagnosis-Related Groups in Europe: towards Efficiency and Quality (EURODRG)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Sweden,France,Netherlands,France,Austria,Estonia,Finland,Spain,Poland,Ireland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2011-12-31
Duration (months): 36.0
Total project cost (EUR): 3700051.01
EU funding (EUR): 2809732.0
Participants: 13
Project status: CLOSED

Payment systems are fundamental to any health care system, introducing powerful incentives and fierce technical design complexities. DRG-systems aim at fairly assessing the costs of patient treatment, taking into account measurable patient characteristics such as diagnosis or comorbidity – but to a varying degree also interventions chosen. Using a representative sample of inpatient data on 10-12 “care episodes” (representing different medical specialties, diagnostic/ therapeutic procedures, usage of innovative devices &amp; drugs) from hospitals in 10 EU countries (AUT, ENG, EST, FIN, FRA, GER, NET, POL, SPA, SWE), the EuroDRG Project aims at studying the importance of structural factors such as wage levels vis-à-vis established patient variables and “medical decision variables” (procedures or using new and emerging technologies) to explain variation in costs within and between European countries. This will allow fair efficiency comparisons among EU hospitals to ensure that DRG-systems provide the intended incentives. A second objective is to investigate the role the quality of care plays to explain costs, an area with practically no European studies but potentially important policy implications. To achieve its objectives, the project is organised in phases: 1. Analysis of national DRG-systems and development of a methodology for trans-national analysis; 2. Trans-national DRG issues - hospital cost functions, efficiency and quality; 3. Translation into practice, synthesis and recommendation. To achieve a high scientific quality and a high policy impact, the strategy involves (based on the successful FP6 HealthBASKET project): encouraging partners to publish in peer-reviewed journals; using excellent links to major international organisations; establishing an EU-wide hospital “benchmarking club”; organising seminars at major conferences; a final conference with invited experts; involving representatives from countries with emerging DRG-systems (Bulgaria, China, India).

Keywords: diagnosis related groups,hospitals,costs,efficiency,quality,benchmarking
Genomic approaches to metabolite exploitation from Xenorhabdus, Photorhabdus (GAMEXP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Thailand,United Kingdom,United Kingdom,Germany,Viet Nam
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2012-08-31
Duration (months): 42.0
Total project cost (EUR): 3403680.0
EU funding (EUR): 2689160.0
Participants: 6
Project status: CLOSED

The majority of compounds used to treat diseases come from a single group of organisms, the actinomycetes. This over-reliance on a single organism to produce the worlds drugs is a major problem for the development of compounds with alternative modes of action which can overcome and delay the onset of drug resistance. To address this problem we will form an international multi-disciplinary group of experts to bioprospect for biologically active natural products. The central aim of this programme is to start rapidly deriving novel drugs from non-actinomycete sources. We will isolate novel strains of the proven but not well-explored drug producers Xenorhabdus and Photorhabdus. These bacteria will be isolated from insect pathogenic nematodes and characterized taxonomically (WP1) and strains will be analyzed for the production of novel compounds (WP2). This library of compounds will then be tested against a broad set of targets including bacteria, fungi, protozoans, nematodes, insects, and mammalian cell cultures (WP3). The five most productive bacterial strains will then be fully sequenced and used to construct genomic libraries. These libraries will be used to generate recombinant clones in heterologous hosts, enabling fast and efficient biotechnological production of the bioactive compounds (WP4). To ensure efficient interactions and comparability of results, especially regarding the bioactivity data, training sessions will be organized with seminars and hands on experience for each of the groups at a central site (WP5). Robust patent stuctures will ensure efficient technology transfer to our industrial partners (WP6) and overall coordination of the scientific and training programs will be overseen by WP7.

Keywords: drug discovery,multiple-target bioactivity testing,xenorhabdus,photorhabdus,exploitation
European network for global cooperation in the field of AIDS & TB (EUCO-NET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Germany,Belgium,Italy,Germany,Russian Federation,South Africa,Argentina,Brazil,Germany,Colombia,Germany,India
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-11-01
End date: 2010-04-30
Duration (months): 18.0
Total project cost (EUR): 925804.0
EU funding (EUR): 827264.0
Participants: 14
Project status: CLOSED

Background Tuberculosis and HIV/AIDS are on the rise worldwide, representing a global public health problem with considerable mutual interaction: TB is the leading cause of mortality for people living with HIV/AIDS, and HIV is the most potent force driving the TB epidemic in countries with a high prevalence of HIV . Especially in rural areas of Africa, Latin America, India and Russia both diseases form a deadly combination affecting large populations: In 2006, 39.5 million people suffered from HIV , and 2 billion people were infected with Mycobacterium tuberculosis, the causative agent of TB . Approximately 11 million people are “co-infected” with both diseases. Up to now, there is a massive failure to respond to the dual epidemic in an integrated way , and despite an increasing awareness worldwide, greater commitment and increased funding, current prevention and treatment efforts as well as coordinated research initiatives need to be strengthened to address the challenge of TB-HIV coinfection . TB and HIV programmes worldwide still work largely in isolation from each other and are focussing on national levels, although the urgent need to combat HIV and TB is recognized internationally. Additionally, scientists still primarily work with colleagues from the same field of research instead of collaborating with partners in complementary fields. Objective The objective of the support action is to provide an overview of the state of the art in HIV and TB research and disease management in the different partner countries, to identify global research priorities and to boost international cooperation between leading HIV and TB experts from Europe and those countries mainly affected by the two diseases - Russia, Latin America, South Africa and India.

Keywords: tuberculosis,mtb,aids,hiv,network,research and disease management,international cooperation,future research priorities,country report,road map,india,russia,south africa,latin america
Development of High Performance Diagnostic Array Replication Technology (HIPERDART)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Sweden,Switzerland,Italy,Spain,Germany,Netherlands
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2012-12-31
Duration (months): 48.0
Total project cost (EUR): 3956572.2
EU funding (EUR): 2999882.0
Participants: 7
Project status: CLOSED

Development of High Performance Diagnostic Array Replication Technology (HiPerDART) As with any new technology, the use of DNA microarrays has presented a number of important obstacles, many of which have limited their ability to move beyond research applications. For example, the data obtained from a traditional microarray experiment can fluctuate dramatically due to small perturbations in assay conditions. This fact, when coupled to the often extensive workflows required to perform an assay, has caused many experts to conclude that microarrays are not well suited to clinical applications. Other factors as limited content flexibility and high production costs contribute to this negative image. It is the aim of the present HiPerDART project to develop a higher standard (clinical) microarray technology platform, by proposing a highly innovative probe printing technology, called Supramolecular NanoStamping (SuNS). Moreover, since at the same time in HiPerDART both assay workflow will be minimized and signal-to-noise ratios will be improved, our technology platform promises to dramatically improve the reliability (reproducibility and costs) of these (medical) tests. Furthermore, in an industry dominated by U.S. players, it is imperative to establish a strong European presence at this early stage in the development of the clinical market. By using a complex disease as colon cancer to prove the strength of the HiPerDART microarray technology platform, already in the limited lifetime of this project a first HiPerDART diagnostic microarray test will be validated.

Keywords: microarray,high performance diagnostic array replication technology,suns (printing) technology,array hybridization
Targeting the Leishmania kinome for the development of novel anti-parasitic strategies (LEISHDRUG)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Korea, Republic of,Tunisia,Uruguay,Israel,United Kingdom,Italy,Spain,Spain,France,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2008-10-01
End date: 2012-03-31
Duration (months): 42.0
Total project cost (EUR): 4491633.0
EU funding (EUR): 2852232.0
Participants: 13
Project status: CLOSED

Visceral leishmaniasis is caused by the protozoan parasites Leishmania donovani and Leishmania infantum and is a potentially fatal disease in endemic areas around the world. During the infectious cycle, Leishmania alternate between the insect promastigote stage and the vertebrate aflagellate amastigote stage that proliferates inside infected host macrophages provoking the pathology of the disease. This consortium uses a highly interdisciplinary approach to reveal Leishmania signaling molecules associated with amastigote virulence, with the major aim to exploit parasite-specific pathways for anti-leishmanial drug development. We use innovative drug screening concepts not applied previously on parasitic systems. We will utilize visual high-content screening to discover compounds capable to kill intracellular Leishmania amastigotes without deteriorating the host cell. This phenotype-based strategy relies on fluorescent parasites and macrophages as read-outs and will allow simultaneous assessment of anti-leishmanial activity and host cell toxicity under physiological conditions. We will apply a target-based strategy utilizing recombinant Leishmania protein kinases for inhibitor identification and structure-guided drug design. The identification of appropriate target kinases, with only limited homology to their mammalian counterparts will rely on in silico analysis by applying novel bioinformatic tools developed by consortium members, and in vitro assay based on their phospho-transferase activity towards recombinant Leishmania phospho-proteins. The major objectives of this proposal are (i) to screen small molecule and peptide libraries for hit compounds with leishmanicidal activity using phenotype- and target-based strategies, (ii) to identify anti-parasitic lead compounds and assess their pharmacokinetic profiles using cell-culture and experimental infection models for leishmaniasis, and (iii) to initiate lead optimization by structure-based drug design.

Keywords: leishmania,kinome,drug screen,target screen,proteomics
Learning from International Networks about Errors and Understanding Safety in Primary Care (LINNEAUS EURO -PC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: United Kingdom,Germany,Austria,United Kingdom,Netherlands,Poland,Greece,United Kingdom,Spain,Denmark
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2013-05-31
Duration (months): 51.0
Total project cost (EUR): 2760332.86
EU funding (EUR): 2461250.0
Participants: 12
Project status: CLOSED

There is a deficit in activity related to patient safety in primary care and the primary care/secondary care interface in Europe. This deficit relates to research, to sharing of information, to learning and to collaboration. This co-ordination action will specifically address issues addressed in the call through: (1)The development of a taxonomy of adverse events and errors. (2) Identifying best clinical practice and the way that it improves patient safety through an understanding of decision making and medication errors in primary care. (3) Achieve consensus on the measurement of safety culture and leadership in the primary care context and develop agreement on indicators which can be used to assess patient safety and improvements in safety culture. (4) Enhancing existing knowledge from quality improvement techniques which are widely used in the primary care setting and applying these to learning cycles for improvements in patient safety. (5) Develop a reporting system which can be used for identifying errors in primary care in countries where activities related to patient safety in primary care are in a nascent state and develop an accreditation framework for patient safety in these nascent organisations. (6) Identifying methods to involve patients in patient safety initiatives in primary care. (7) Identifying communication-related threats at the primary-secondary care interface and developing intervention strategies to overcome these. Building up an existing network of researchers into a pan European network, this co-ordination action will extend the current knowledge and experience from countries where the importance of patient safety is nationally recognised to countries where it is less developed, ensure that there is an appropriate focus on primary care and encourage co-operation and collaboration for future interventions through large scale trials. We aim to substantially increase the level of activity in relation to sharing information through workshops and seminars.

Keywords: primary care,patient safety,taxonomy,diagnostic errors,medication errors,safety culture,learning
Definition of a genetic network involved in congenital heart disease. (CARDIOGENET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,United Kingdom,Netherlands,United Kingdom,France,Germany,Germany
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-03-01
End date: 2013-02-28
Duration (months): 48.0
Total project cost (EUR): 3929129.91
EU funding (EUR): 2680000.0
Participants: 7
Project status: CLOSED

This application focuses on transcriptional networks that govern the development of a heart region commonly affected by congenital heart disease (CHD). The major goal is to provide the clinical and basic science research communities with a validated list of interconnected genes required for normal heart development. To achieve this goal, we have recruited 6 European groups of scientists strongly committed to CHD research. The participants bring to the consortium significant resources and credible synergy. The entry point for the interrogation and perturbation of cardiogenic gene networks will be the transcription factor Tbx1, the major gene for 22q11.2 deletion syndrome, a common genetic cause of CHD. The project has three specific aims: 1) To define the roles and interactions of T-box transcription factors in cardiac outflow tract (OFT) development. Our hypothesis is that a critical balance of Tbx1, 2, and 3 is required to regulate homeostasis of a specific population of cardiac progenitors and their interactions with non-cardiogenic cells. 2) To define gene networks perturbed in OFT developmental defects. Innovative approaches will identify the transcriptional targets and protein interactors of Tbx1. Candidate genes will be validated in vitro and in vivo using mouse and zebrafish models. In addition, we will perform extensive transcriptome analyses using biopsy material from CHD patients in order to integrate animal and patient data. 3) To integrate gene expression, cell lineage distribution and phenotype data. Normal heart morphology is achieved through a concerted gene expression program and the integration of molecular signals and tissue interactions. Aided by 3-dimensional reconstruction of gene expression patterns and phenotypic information, we will integrate different types of data to develop models of CHD pathogenesis. Teamwork will be enhanced by shared technologies that provide homogeneity and comparability of data between the participating labs.

Keywords: t-box transcription factors,digeorge syndrome,cardiac outflow tract,second heart field
Scoping study of approaches to Brokering knowledge and Research Information to support the Development and Governance of health systems in Europe (BRIDGE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Coordination and support actions
Countries involved: Switzerland
Call:  (FP7-HEALTH-2007-B, 2007)
Start date: 2009-01-01
End date: 2011-04-30
Duration (months): 28.0
Total project cost (EUR): 887100.0
EU funding (EUR): 790997.0
Participants: 1
Project status: CLOSED

Good health systems’ development and governance depend on well-informed decisions. However, health policymakers often formulate strategies and reforms without using the best available knowledge or information. Even where researchers, statisticians and other actors are generating evidence on performance, effectiveness or models of governance or service delivery, there is often a complex disjuncture between information and policy. It relates to problems with the • relevance, quality, and timeliness of the information being produced • way knowledge is ‘brokered’ or transferred into policy • policymaking process itself and how it intersects with technical inputs. What is missing is an effective bridge between the worlds of health system information, and policy making. This scoping study will explore current efforts to broker information for policy and bridge the information–action gap. It will be carried out by the European Observatory on Health Systems and Policies, a well-established partnership of international organizations, governments and academics that focuses on bringing health system information to those who can act on it. The Observatory will mobilize its extensive networks and bring the right international experts together under a single umbrella to map existing approaches to knowledge brokering and to identify what we know and what we don’t about them. The study will: • develop a framework for organizing and understanding models of brokering research into policy • describe and compare EU member states’ experiences with • information-packaging and interactive knowledge-sharing mechanisms • national and European models for knowledge brokering • undertake country case studies to explore how knowledge-brokering approaches intersect with and support policymaking. The study will set out the implications that comparative research on knowledge brokering has for the organisation and management of information systems in the EU.

Keywords: research,policy,health,evidence,health systems,healthcare,information,governance,free movement of service providers,brain drain